Summary
LTF-RT (research code LY3437943) is a synthetic research peptide developed as a triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is widely studied in comparative receptor pharmacology and energy-metabolism literature.
Overview
LTF-RT is a synthetic, lipidated peptide engineered to engage three distinct incretin- and glucagon-family receptors. The triple-receptor design distinguishes it from earlier dual-receptor (LTF-TZ) and single-receptor (LTF-SM) compounds in the same research lineage.
Research Background
LTF-RT was described by Coskun et al. (2022) as part of a research program at Eli Lilly aimed at multi-receptor incretin agonism. The design rationale draws on receptor-pharmacology observations across the GLP-1, GIP, and glucagon-receptor families and on energy-metabolism work that examined how concurrent receptor engagement modulates downstream signaling in preclinical models.
Mechanisms Studied
In-vitro receptor-binding and cAMP-accumulation assays have characterized LTF-RT as a balanced agonist across the three target receptors with potencies in the picomolar range. Mechanistic interest centers on the differential potency at each receptor, the cAMP signaling profile, and how concurrent glucagon-receptor engagement modulates energy-expenditure pathways in animal models.
Published Research Summary
The original characterization by Coskun et al. (2022, Cell Metabolism) describes LTF-RT’s receptor-binding profile, cellular signaling, and effects on energy metabolism in preclinical models. Subsequent reviews position LTF-RT alongside LTF-SM and LTF-TZ in the emerging incretin-pharmacology literature.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.
References & Published Research
- Coskun T et al. — LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist for the treatment of metabolic disease (preclinical characterization)
- Knerr PJ et al. — Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
- Müller TD et al. — The new biology and pharmacology of glucagon (review of glucagon-receptor pharmacology)